Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. - Wikidata - awgldk - TriplyDB

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

http://www.wikidata.org/entity/Q34557101

about

Rifaximin for people with hepatic encephalopathy Use of rifaximin in gastrointestinal and liver diseases Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications Profile of rifaximin and its potential in the treatment of irritable bowel syndrome Second and third line treatment options for Helicobacter pylori eradication Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy The impact of antibiotics on growth in children in low and middle income countries: systematic review and meta-analysis of randomised controlled trials 'Rescue' therapies for the management of Helicobacter pylori infection.Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.The pathogenesis of gastrointestinal bacterial overgrowth.Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract.Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.Rifaximin treatment for symptoms of irritable bowel syndrome.Rifaximin pharmacology and clinical implications.Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?Antibiotics for the treatment of irritable bowel syndrome Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota.Use of antibiotics in the treatment of inflammatory bowel disease.Emerging therapies in the treatment of Clostridium difficile-associated disease.Past, present, and future therapies for Clostridium difficile-associated disease.High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center.Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders.Rifaximin for the treatment of irritable bowel syndrome.Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.Emerging therapies for the treatment of Helicobacter pylori infections.Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies.Rifaximin has minor effects on bacterial composition, inflammation and bacterial translocation in cirrhosis; A randomized trial.The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease.Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth.Rifaximin in the management of colonic diverticular disease.Rifamycin SV MMX for the treatment of traveler's diarrhea.Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis.Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation.

P2860

Q24187627-3136B2E2-2202-4374-936D-7D85F7B096AE Q26740201-4AF4AB9F-259A-4AC8-9885-2160C1F1F918 Q26775927-7210A05B-2E85-4B61-9AC9-5F78F8AF169F Q26829363-E688ADF3-99D7-4DB3-972C-CA96C017D72D Q26829666-5E676E88-1EF1-4BBC-B33C-71A08AF30A70 Q27001540-65BC58C8-0653-40D1-9731-215F3436EDCB Q28236913-AA81D255-9C45-4537-AE8B-4260571B9719 Q28660009-6C7C5C2A-65F1-44D4-BA40-FAFF61B3A211 Q33371187-2A95BA00-00B2-48CB-B2F4-5DB89D6EF50D Q33958376-8C0A8765-0F0F-4741-8598-966941A8F00A Q34557095-489062C9-689F-4F1F-80A9-63AAC7BB6415 Q34557108-A9FF4191-AE9C-4A25-899B-6DC8EFCFABAB Q34566470-CE1C086D-A5B1-484F-816B-4DDC540F95A4 Q34588803-2AA79811-EAF1-455D-9EE8-C292EC9D469D Q34607677-396ED016-64D0-449F-8000-5FBD0A9F9244 Q34757166-7FADCB3A-58B9-4F22-9F79-0A5A963BFC1F Q35558415-FB79F3C0-E2E5-47D0-B6B0-4BC8CCBA43F8 Q35691133-D339117A-B5A9-44E2-BE43-1D683AC5FE81 Q35855737-E9041B3E-6CA4-479A-B476-1385AD772D03 Q35855740-AFF918B2-598B-4E45-A1AF-A5B54A8A014F Q36009729-5C89B199-964B-4210-A346-B599174FC179 Q36171542-E3CD225C-8ACE-4963-99D6-37CDBFCC9A0E Q36521201-29A8D941-0152-4544-B95E-9993132D3C2E Q36659957-358DC326-CF50-4E7B-B560-0FF6B87E92CB Q36674768-0ECA6739-A6AB-49C2-A568-CB54AF5C8D19 Q37478838-625D618F-88F7-4DC0-946B-655A3E3D664C Q37564122-E0C79676-0710-4398-A5E9-48864F6C0AA9 Q37976477-E56F3049-6623-4899-A854-8CE2EC021209 Q38340085-4B5AB4D5-A2BB-4ABF-9533-C44DA75BA843 Q38424698-A8374FB9-35C8-40D5-A688-CF0C462CA134 Q38633511-73FB2A58-4FF2-423E-99E5-BD324CBE84CA Q38696806-B18D6234-1EC8-4F63-B2E5-5176673B2ECE Q39035437-434D0255-15BA-4723-8417-5532B531FAB8 Q39081757-34E4D2B3-762E-4D83-8142-D51DB94F6EDE Q39295479-22468A19-EF92-4E09-B70E-0AA3E97DA581 Q39428832-9E2DA18B-2546-482E-9FA9-0C085589CC50 Q39455595-1B9BE9EA-0EAE-4928-A772-8EDCEAAD0159 Q39665248-DF1DA3E5-4DA2-4967-A925-3C060FCF071C Q39781817-2EAB1996-F60A-4007-89C1-02ED09EA1941 Q39901709-6036F61E-8A08-48CC-8068-5955365A3B75

P2860

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

http://www.wikidata.org/entity/Q34557101

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

@ast

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

@en

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

@nl

type

label

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

@ast

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

@en

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

@nl

prefLabel

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

@ast

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

@en

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

@nl

P1433

Q34557101-2D255E86-8131-4B1B-850A-10478F44B7C3

P1476

Q34557101-0D00D4CE-4960-4219-B45C-D3AE6B21966E

P2093

Q34557101-153AA4FF-CD27-4597-BEC9-3AFA4C43E336

Q34557101-17A5528D-7360-47DD-B670-FCA57256DAEC

P2860

Q34557101-02C52BA4-F374-4F33-A7AA-AE86DBF98918

Q34557101-04213027-CD18-492B-88D2-D9FCF2ED8273

Q34557101-054CD4A5-EF87-4D72-899C-3E7411E3FF33

Q34557101-0588D278-9E4B-46BF-88CA-A686930BC040

Q34557101-07A4BA60-6FCA-4240-9C62-52B0A17FCBD9

Q34557101-0EF5B86E-091D-477B-8BFE-C390996888F8

Q34557101-10EF7448-E35C-46C6-8606-A2C545645D87

Q34557101-139FA6EA-DD68-46A3-9D84-20DFA5B2EEA4

Q34557101-1631B50C-DC6B-459E-8070-754790EE7EF7

Q34557101-1BDA14C8-86F2-40B6-A659-A575117209EE

P304

Q34557101-02AE0EF6-FB46-4AB9-ABB2-4255E633CCC1

P31

Q34557101-387F04F9-7D93-47E5-9C0E-E9E6EB9501B9

P356

Q34557101-940EDE52-D4FF-4EB4-900A-FA1473526098

P478

Q34557101-4FBB45F6-8002-4A19-ABB4-21D7256A6998

P577

Q34557101-A3B46C93-5135-4355-B9ED-5AF8891234A3

P5875

Q34557101-59C4B7E0-714D-4FDE-9919-518F5F369155

P698

Q34557101-1DC2D13A-94AC-4A11-9724-4D353B1E07D8

P921

Q34557101-EC2F19ED-2DA3-49C7-BC1C-29021A35B5C0

P356

P1433

P1476

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.

@en

P2093

Carmelo Scarpignato

http://www.w3.org/2001/XMLSchema#string

Iva Pelosini

http://www.w3.org/2001/XMLSchema#string

P2860

Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

Dysbiosis in inflammatory bowel disease

Gut flora in health and disease

Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration

Helicobacter pylori infection and the development of gastric cancer

Pathophysiology and impact of enteric bacterial and protozoal infections: new approaches to therapy.

Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis.

Drug interactions between oral contraceptives and antibiotics.

Antibiotic side effects.

P304

36-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000081990

http://www.w3.org/2001/XMLSchema#string

P478

51 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7881816

http://www.w3.org/2001/XMLSchema#string

P698

15855748

http://www.w3.org/2001/XMLSchema#string

P921